Safety and Tolerability of PRO-185

Inclusion Criteria: * Being clinically healthy * Having the ability to grant a signed informed consent * Being able and willing to comply with the programmed visits, treatment plan and other procedures of this study. * Age between 18 and 45 years * Women in child-bearing age must assure the continuation (start ≥ 30 days previous to the signing of the ICF) of a hormonal contraceptive method or a intrauterine device (IUD) during the period of the study. * Best corrected visual acuity equal of better than 20/30 in both eyes. * Vital signs within normal ranges. * Intraocular pressure ≥10 and ≤ 21 mmHg Exclusion Criteria: * Using any kind of topic ophthalmic products * Presenting allergies to naphazoline or the history of intolerance to nasal decongestants or ocular vasoconstrictive products. * History of diagnosis of suspicion of primary angle closure, primary angle closure or closed angle glaucoma. * History of iridotomies or waiting for this procedure to take place. * Conjunctival hyperemia grade 3 or 4 according to Efron scale. * Ocular surface staining equal or greater to 3 in the SICCA scale, for any eye. * Using medications or herbology products, through any route of administration. * Pregnant, breastfeeding or women who plan to get pregnant during the period of the study. * Previous participation in any clinical study 90 days prior to the inclusion in the present study. * Previous participation in this study. * Using contact lenses which cannot be suspended during the p…